Smith & Nephew exits tough half year
The British medtech firm has downgraded its full-year expectations after getting off to a bad start in 2022, where Covid-19, a logistics crisis, and inflation have made marks.
by marketwire, translated by daniel pedersen
Smith & Nephew has left behind a difficult first half of the year characterized by supply chain issues, which have led to disappointing results for the firm.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Coloplast is phasing out natural gas
For subscribers
Boston Scientific exceeds most expectations in Q2
For subscribers
